Short Interest Worth Watching: Could Chromadex Corporation (NASDAQ:CDXC) Change Direction After Less Shorts?

November 29, 2016 - By Peter Erickson   ·   0 Comments

Short Interest Worth Watching: Could Chromadex Corporation (NASDAQ:CDXC) Change Direction After Less Shorts?

The stock of Chromadex Corporation (NASDAQ:CDXC) registered a decrease of 5.25% in short interest. CDXC’s total short interest was 1.28M shares in November as published by FINRA. Its down 5.25% from 1.35 million shares, reported previously. With 86,100 shares average volume, it will take short sellers 15 days to cover their CDXC’s short positions. The short interest to Chromadex Corporation’s float is 4.45%. The stock increased 3.98% or $0.1 during the last trading session, hitting $2.61. Chromadex Corp (NASDAQ:CDXC) has declined 41.74% since April 26, 2016 and is downtrending. It has underperformed by 47.00% the S&P500.

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control services and products to the natural products industry. The company has a market cap of $99.73 million. The Firm allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. It currently has negative earnings.

CDXC Company Profile

Chromadex Corporation, incorporated on June 19, 2008, and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control services and products to the natural products industry. The Firm allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Firm operates through three divisions: Ingredients, Core standards and contract services, and Scientific and regulatory consulting. Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients to the manufacturers of consumer products in various industries, including the nutritional supplement, food and beverage, and animal health industries. Core standards and contract services segment includes supply of phytochemical reference standards, which are small quantities of plant compounds used to research an array of attributes, reference materials and related contract services. Scientific and regulatory consulting segment provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

More recent Chromadex Corp (NASDAQ:CDXC) news were published by: Reuters.com which released: “BRIEF-Chromadex Corp says Chromadex Inc entered into second addendum to ni…” on September 19, 2016. Also Globenewswire.com published the news titled: “ChromaDex Launches New Patented Ingredient – IMMULINA(TM) – a Powerful …” on September 10, 2015. Globenewswire.com‘s news article titled: “ChromaDex and Collaborators Report Unexpected Discovery of Novel Biomarkers of …” with publication date: August 12, 2015 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Peter Erickson


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>